Myriad Genetics Inc (MYGN) — Titan Protect Analysis

MYGN

Myriad Genetics Inc

Healthcare · ·

$4.57

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$397M

Total market value of the company

Trailing P/E

N/A

Forward P/E

27.83

Based on estimated future earnings — lower means cheaper

Rev Growth

-20.8%

Year-over-year revenue change

Profit Margin

-41.3%

How much profit the company keeps from each dollar of revenue

ROE

-23.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.75

+26% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 8 analysts covering this stock

About Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious

https://www.myriad.com

Country: United States Employees: 2,700 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.706

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0815

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.625

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-54.8%

Historical annualised return based on price data

Max Drawdown

-87.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.64

Significantly more volatile than the market

52W High

$8.59

47% below the year high

52W Low

$3.53

29% above the year low

Avg Volume

1,914,919

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.31

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

32.85

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

68.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-21.4%

Profit from core operations before interest and tax

Free Cash Flow

$-46,062,500

Negative — the business is spending more than it generates

Revenue (TTM)

$557M

Total revenue over the last 12 months

Net Income

$-230,000,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$5.75

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go